-- 藝康集團(Ecolab,股票代號:ECL)週三宣布,其位於韓國東灘的生物製程應用實驗室正式啟用,這是該公司在亞洲的首個此類設施。 藝康集團表示,實驗室支援全方位的製程開發活動,涵蓋從早期測試到大規模生產模擬研究的各個階段。此外,該實驗室還能促進與藝康專家的緊密合作,進而提升純化製程、提高效率,並協助產品達到商業化標準。 藝康集團股價當日下跌超過3%。
Price: $258.64, Change: $-8.32, Percent Change: -3.12%
-- 藝康集團(Ecolab,股票代號:ECL)週三宣布,其位於韓國東灘的生物製程應用實驗室正式啟用,這是該公司在亞洲的首個此類設施。 藝康集團表示,實驗室支援全方位的製程開發活動,涵蓋從早期測試到大規模生產模擬研究的各個階段。此外,該實驗室還能促進與藝康專家的緊密合作,進而提升純化製程、提高效率,並協助產品達到商業化標準。 藝康集團股價當日下跌超過3%。
Price: $258.64, Change: $-8.32, Percent Change: -3.12%
Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%
Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.